The α-Thalassemias

New England Journal of Medicine

Volumn 371, Issue 20, 2014, Pages 1908-1916

  Piel, Frédéric B ^a   Weatherall, David J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA THALASSEMIA; BETA THALASSEMIA; CHORION VILLUS SAMPLING; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; EPIDEMIOLOGIC TRANSITION; EPIDEMIOLOGICAL MONITORING; FETUS HYDROPS; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GEOGRAPHIC DISTRIBUTION; HEMATOLOGICAL PROCEDURE; HEMOGLOBIN H DISEASE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INCIDENCE; IRON DEFICIENCY; POLYMERASE CHAIN REACTION; POPULATION GROWTH; POPULATION MIGRATION; PRENATAL DIAGNOSIS; PREVALENCE; PROPHYLAXIS; REVIEW; ALPHA-THALASSEMIA; CHILD; GENETICS; MEDICAL GEOGRAPHY; QUALITY ADJUSTED LIFE YEAR;

ALPHA-THALASSEMIA; CHILD; GEOGRAPHY, MEDICAL; HUMANS; PRENATAL DIAGNOSIS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84910138945     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1404415     Document Type: Review

References (58)

1. Weatherall DJ, Clegg JB. Thalassemia-a global public health problem. Nat Med 1996;2:847-9.
2. Weatherall DJ. The thalassaemias. BMJ 1997;314:1675-8.
3. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.
4. Erratum, N Engl J Med 1999;341:1407.
5. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480-7.
6. Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986;321:744-50.
7. Chui DH. Alpha-thalassaemia and population health in Southeast Asia. Ann Hum Biol 2005;32:123-30.
8. Modiano G, Morpurgo G, Terrenato L, et al. Protection against malaria morbidity: near-fixation of the alpha-thalassemia gene in a Nepalese population. Am J Hum Genet 1991;48:390-7
9. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Mem Fund Q 1971;49:509-38.
10. Chui DHK, Waye JS. Hydrops fetalis caused by α-thalassemia: an emerging health care problem. Blood 1998;91:2213-22.
11. Vichinsky EP. Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 2005;1054:18-24.
12. Weatherall D. The inherited disorders of haemoglobin: an increasingly neglected global health burden. Indian J Med Res 2011134:493-7
13. Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010;115:4331-6.
14. Harteveld CL, Higgs DR. Alpha-thalas-saemia. Orphanet J Rare Dis 2010;5:13.
15. Higgs DR, Weatherall DJ. The alpha thalassaemias. Cell Mol Life Sci 2009;66: 1154-62.
16. Vichinsky EP. Clinical manifestations of α-thalassemia. Cold Spring Harb Per-spect Med 2013;3:a011742.
17. Galanello R, Cao A. Gene test review: alpha-thalassemia. Genet Med 2011;13: 83-8.
18. Giardine B, Borg J, Viennas E, et al. Updates of the HbVar database of human hemoglobin variants and thalassemia mutations. Nucleic Acids Res 2014;42: D1063-D1069.
19. Weatherall DJ, Clegg JB. The thalas-saemia syndromes. 4th ed. Oxford, England: Blackwell Science, 2001.
20. Higgs DR. Alpha-thalassaemia. Bail-lieres Clin Haematol 1993;6:117-50.
21. Chui DHK, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003;101:791-800.
22. Fucharoen S, Viprakasit V. Hb H disease: clinical course and disease modifiers. Hematology Am Soc Hematol Educ Program 2009:26-34.
23. Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med 2011;364:710-8.
24. Thein SL. Genetic modifiers of beta-thalassemia. Haematologica 2005;90:649-60.
25. Williams TN, Mwangi TW, Wambua S, et al. Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet 2005;37:1253-7.
26. Ma SK, Au WY, Chan AY, Chan LC. Clinical phenotype of triplicated alpha-globin genes and heterozygosity for be-ta0-thalassemia in Chinese subjects. Int J Mol Med 2001;8:171-5.
27. Giordano PC, Bakker-Verwij M, Harte-veld CL. Frequency of alpha-globin gene triplications and their interaction with beta-thalassemia mutations. Hemoglobin 2009;33:124-31.
28. Weatherall DJ, Higgs DR, Bunch C, et al. Hemoglobin H disease and mental retardation: a new syndrome or a remarkable coincidence? N Engl J Med 1981;305: 607-12.
29. Leung KY, Lee CP, Tang MH, et al. Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn 2004;24:899-907.
30. Vichinsky EP. Alpha thalassemia major-new mutations, intrauterine management, and outcomes. Hematology Am Soc Hematol Educ Program 2009;35-41.
31. Wonke B, Modell M, Marlow T, Khan M, Modell B. Microcytosis, iron deficiency and thalassaemia in a multi-ethnic community: a pilot study. Scand J Clin Lab I n vest 2007;67:87-95.
32. Pasvol G. Does alpha+-thalassaemia protect against malaria? PLoS Med 2006; 3(5):e 235.
33. Hedrick PW. Population genetics of malaria resistance in humans. Heredity (Edinb) 2011;107:283-304.
34. Erratum, Heredity (Edinb) 2011;107:602.
35. Penman BS, Habib S, Kanchan K, Gupta S. Negative epistasis between α+ thalassaemia and sickle cell trait can explain interpopulation variation in South Asia. Evolution 2011;65:3625-32.
36. Penman BS, Pybus OG, Weatherall DJ, Gupta S. Epistatic interactions between genetic disorders of hemoglobin can explain why the sickle-cell gene is uncommon in the Mediterranean. Proc Natl Acad Sci USA 2009;106:21242-6.
37. Weatherall DJ. The importance of mi-cromapping the gene frequencies for the common inherited disorders of haemoglobin. Br J Haematol 2010;149:635-7.
38. Ganczakowski M, Bowden DK, Mait-land K, et al. Thalassaemia in Vanuatu, south-west Pacific: frequency and haema-tological phenotypes of young children. Br J Haematol 1995;89:485-95.
39. Weatherall D, Akinyanju O, Fucha-roen S, Olivieri N, Musgrove P. Inherited disorders of hemoglobin. In: Jamison DT, Breman JG, Measham AR, et al., eds. Disease control priorities in developing countries. 2nd ed. Washington, DC: World Bank, 2006:663-80.
40. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
41. Murray CJL, Lopez AD. Measuring the global burden of disease. N Engl J Med 2013;369:448-57.
42. Modell B, Kuliev AM. A scientific basis for cost-benefit analysis of genetics services. Trends Genet 1993;9:46-52.
43. Ostrowsky JT, Lippman A, Scriver CR. Cost-benef it analysis of a thalassemia disease prevention program. Am J Public Health 1985;75:732-6.
44. Ahmadnezhad E, Sepehrvand N, Jah-ani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in West-Azerbaijan province of Iran. Int J Prev Med 2012;3:687-92.
45. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz EA. Cost-benefit analysis of a national thal-assaemia prevention programme in Israel. J Med Screen 1998;5:120-6.
46. Koren A, Profeta L, Zalman L, et al. Prevention of β thalassemia in northern Israel-a cost-benefit analysis. Mediterr J Hematol Infect Dis 2014;6:e2014012.
47. Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess 1999;3:1-186.
48. Padilla CD, Dans LF, Estrada SC, Ta-mondong MR Jr, Laceste JJ, Bernal RM. Cost-benefit analysis of newborn screening for galactosemia in the Philippines. Southeast Asian J Trop Med Public Health 2003;34:Suppl 3:215-20.
49. Petrou M, Brugiatelli M, Old J, et al. Alpha thalassaemia hydrops fetalis in the UK: the importance of screening pregnant women of Chinese, other South East Asian and Mediterranean extraction for alpha thalassaemia trait. Br J Obstet Gyn-aecol 1992;99:985-9.
50. Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood 2000;95:360-2.
51. Weatherall DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci 2010;1202:17-23.
52. Padilla CD, Therrell BL. Newborn screening in the Asia Pacific region. J Inherit Metab Dis 2007;30:490-506.
53. de Silva S, Fisher CA, Premawardhena A, et al. Thalassaemia in Sri Lanka: implications for the future health burden of Asian populations. Lancet 2000;355:786-91.
54. Mills A. Health care systems in low-and middle-income countries. N Engl J Med 2014;370:552-7.
55. Weatherall D. 2003 William Allan Award address: the thalassemias: the role of molecular genetics in an evolving global health problem. Am J Hum Genet 2004; 74:385-92.
56. Higgs DR. The molecular basis of α-thalassemia. Cold Spring Harb Perspect Med 2013;3:a011718.
57. Benz EJ Jr. Newborn screening for α-thalassemia-keeping up with globalization. N Engl J Med 2011;364:770-1.
58. Kassebaum NJ, Weatherall D, Naghavi M, Murray CJL. A systematic global analysis of death and disability due to haemo-globinopathies and haemolytic anaemias between 1990 and 2010. Lancet 2013;381 (Special issue):S73.